Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors

References

• GengR, LiJ. Apatinib for the treatment of gastric cancer. Expert Opin Pharmacother. 2015;16:117–122. doi:10.1517/14656566.2015.98152625420417
   PubMed Web of Science ®Google Scholar
• RovielloG, RavelliA, FiaschiAI, et al. Apatinib for the treatment of gastric cancer. Expert Rev Gastroenterol Hepatol. 2016;10:887–892. doi:10.1080/17474124.2016.120940727376400
   PubMed Web of Science ®Google Scholar
• LiuX, ZhangY, ChenQ, et al. Pharmacokinetic drug interactions of apatinib with rifampin and itraconazole. J Clin Pharmacol. 2018;58:347–356. doi:10.1002/jcph.101628967981
   PubMed Web of Science ®Google Scholar
• DingJ, ChenX, GaoZ, et al. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos. 2013;41:1195–1210. doi:10.1124/dmd.112.05031023509226
   PubMed Web of Science ®Google Scholar
• ZangerUM, SchwabM. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141. doi:10.1016/j.pharmthera.2012.12.00723333322
   PubMed Web of Science ®Google Scholar
• ChoueiriTK, SonpavdeG, GoldbergRM, LarsonRA, TirnauerJS Toxicity of molecularly targeted antiangiogenic agents: non-cardiovascular effects. UpToDate [homepage on the Internet]; 2014 Available from: https://www.uptodate.com/contents/zh-Hans/toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects.html. Accessed 197, 2019.
   Google Scholar
• US Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for Industry: Clinical Drug Interaction Studies—study Design, Data Analysis, and Clinical Implications (Draft). US Food and Drug Administration; 2017.
   Google Scholar
• HiraideM, MinowaY, NakanoY, et al. Drug interactions between tyrosine kinase inhibitors (gefitinib and erlotinib) and warfarin: assessment of international normalized ratio elevation characteristics and in vitro CYP2C9 activity. J Oncol Pharm Pract. 2019;25:1599–1607. doi:10.1177/107815521880106130253730
   PubMed Web of Science ®Google Scholar
• ChenXF, HouXY, ChenXY, ZhongDF. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma. Yao Xue Xue Bao. 2019;54:360–365.
   Google Scholar
• JinS, ZhangYF, ChenXY, LiuK, ZhongDF. Enantioselective determination of R-warfarin/S-warfarin in human plasma using liquid chromatography-tandem mass spectrometry and its application in a drug-drug interaction study. Yao Xue Xue Bao. 2012;47:105–109.22493814
   PubMedGoogle Scholar
• US Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for Industry: In Vitro Metabolism- and Transporter-Mediated Drug-Drug Interaction Studies (Draft). US Food and Drug Administration; 2017.
   Google Scholar
• LiJ, ZhaoX, ChenL, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10:529. doi:10.1186/1471-2407-10-52920923544
   PubMed Web of Science ®Google Scholar
• YuM, GaoZ, DaiX, et al. Population pharmacokinetic and covariate analysis of apatinib, an oral tyrosine kinase inhibitor, in healthy volunteers and patients with solid tumors. Clin Pharmacokinet. 2017;56:65–76. doi:10.1007/s40262-016-0427-y27379402
   PubMed Web of Science ®Google Scholar
• TachibanaT, KatoM, WatanabeT, MitsuiT, SugiyamaY. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica. 2009;39:430–443. doi:10.1080/0049825090284625219480549
   PubMed Web of Science ®Google Scholar
• VieiraMD, KimMJ, ApparajuS, et al. PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways. Clin Pharmacol Ther. 2014;95:550–557. doi:10.1038/clpt.2014.4324556783
   PubMed Web of Science ®Google Scholar
• LangCC, JamalSK, MohamedZ, MustafaMR, MustafaAM, LeeTC. Evidence of an interaction between nifedipine and nafcillin in humans. Br J Clin Pharmacol. 2003;55:588–590. doi:10.1046/j.1365-2125.2003.01789.x12814453
   PubMed Web of Science ®Google Scholar
• FilgueiraGCO, FilgueiraOAS, CarvalhoDM, et al. Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. Br J Clin Pharmacol. 2017;83:1571–1579. doi:10.1111/bcp.1322628042936
   PubMed Web of Science ®Google Scholar
• TouyzRM, LangNN, HerrmannJ, van den MeirackerAH, DanserAHJ. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension. 2017;70:220–226. doi:10.1161/HYPERTENSIONAHA.117.0885628630211
   PubMed Web of Science ®Google Scholar
• BonoP, RautiolaJ, UtriainenT, JoensuuH. Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol. 2011;50:569–573. doi:10.3109/0284186X.2010.54369621208033
   PubMed Web of Science ®Google Scholar
• LaneS, Al-ZubiediS, HatchE, et al. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol. 2012;73:66–76. doi:10.1111/j.1365-2125.2011.04051.x21692828
   PubMed Web of Science ®Google Scholar
• MaddisonJ, SomogyiAA, JensenBP, JamesHM, GentgallM, RolanPE. The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. Br J Clin Pharmacol. 2013;75:208–216. doi:10.1111/j.1365-2125.2012.04335.x22616655
   PubMed Web of Science ®Google Scholar
• FloraDR, RettieAE, BrundageRC, TracyTS. CYP2C9 genotype-dependent warfarin pharmacokinetics: impact of CYP2C9 genotype on R- and S-warfarin and their oxidative metabolites. J Clin Pharmacol. 2017;57:382–393. doi:10.1002/jcph.81327539372
   PubMed Web of Science ®Google Scholar
• ShaulC, BlotnickS, MuszkatM, BialerM, CaracoY. Quantitative assessment of CYP2C9 genetic polymorphisms effect on the oral clearance of s-warfarin in healthy subjects. Mol Diagn Ther. 2017;21:75–83. doi:10.1007/s40291-016-0247-727878474
   PubMed Web of Science ®Google Scholar
• MorettiLV, MontalvoRO. Elevated international normalized ratio associated with concurrent use of sorafenib and warfarin. Am J Health Syst Pharm. 2009;66:2123–2125. doi:10.2146/ajhp08043619923313
   PubMed Web of Science ®Google Scholar
• PrimeauxB, BurtonB, ShueyS. Supratherapeutic INR resulting from the initiation of warfarin in a patient receiving axitinib. J Oncol Pharm Pract. 2018;24:74–75. doi:10.1177/107815521667785327799609
   PubMed Web of Science ®Google Scholar
• KitadeH, Hiromasa-YamasakiA, HokkokuK, et al. Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer. J Pharma Health Care Sci. 2016;2:15. doi:10.1186/s40780-016-0050-y
   PubMedGoogle Scholar
• ShaikAN, BohnertT, WilliamsDA, GanLL, LeDucBW. Mechanism of drug-drug interactions between warfarin and statins. J Pharm Sci. 2016;105:1976–1986. doi:10.1016/j.xphs.2016.03.01127103011
   PubMed Web of Science ®Google Scholar